Through a project to reduce gaps and inequities in lupus care and treatment, ACR work groups have developed five quality measures focused on clinical and patient-reported outcomes and are integrating them into the RISE registry to support patient care and research.
The ACR highlights essential policy and reporting changes to the Quality Payment Program for performance year 2023 and beyond. Key changes include policies regarding the development of new MIPS Value Pathways and refinement of subgroup participation.
A new award from the ACR’s RISE Registry and the Rheumatology Research Foundation supports early career rheumatology researchers and clinicians who leverage the registry’s real-world data in research projects.
The CMS has reopened the MIPS Extreme and Uncontrollable Circumstances applications for groups, virtual groups and Alternative Payment Model Entities are now open through March 31.
The ACR highlights essential information for providers for 2022 MIPS reporting in the 2022 Medicare Physician Fee Schedule Final Rule, published Nov. 2.
The final rule, issued Nov. 2, finalizes many proposed policies, including a decreased conversion factor, billing for shared visits and teaching services, continuation of telehealth services and inclusion of an ACR-led Merit-Based Incentive Payment System Value Pathway.
On Aug. 6, practice managers, clinicians and researchers gathered with ACR and RISE staff and volunteers to discuss the registry’s development and future.
A better understanding of knowledge gaps and increased engagement of underrepresented communities are needed to diversify rheumatology patient data in clinical datasets, registries and randomized clinical trials.
As the new chair of the Registries & Health Information Technology Committee, William F. Harvey, MD, MSc, hopes to expand representation of patient diversity in the RISE registry and increase the use of registry data for research.
Technological advances, including disease registries such as ACR’s RISE registry, are improving physicians’ ability to connect disparate patients with similar clinical symptoms, driving insights into both rare and common diseases.